Alliance for Pandemic Preparedness
April 22, 2021
Immunogenicity of SARS-CoV-2 Vaccine in Dialysis
Category: Article Summary
Topic: Vaccines and Immunity
Keywords (Tags): antibodies, clinical characteristics
- [Pre-print, not peer-reviewed] 89% of 186 dialysis patients developed anti-SARS-CoV-2 spike antibodies following two doses of mRNA vaccines (Pfizer-BioNTech and Moderna). Among patients without prior SARS-CoV-2 infection (n=148), the seropositivity rate was 86%. A majority (70%) of seropositive patients had maximum titers for anti-spike IgG antibodies at least 14 days after the second dose. No significant differences were observed between the two vaccines.
Lacson et al. (Apr 13, 2021). Immunogenicity of SARS-CoV-2 Vaccine in Dialysis. Pre-print downloaded Apr 22 from https://doi.org/10.1101/2021.04.08.21254779